73094 Federal Register / Vol. 89, No. 174 / Monday, September 9, 2024 / Notices 

potential source(s) of B. multivorans, 

including ice machines and ice 

machine-related products (e.g., cleaning 

solutions). This data collection will 

enable CDC to better ascertain risk 

factors for transmission, potential 

source(s) of ice machine contamination, 

and develop targeted infection 

prevention and control 

recommendations to stop the 

transmission of the bacteria. Since this 

non-research public health response 

remains active, CDC requests approval 

for continued information collection 

activities for a period of three years. 

There are no proposed changes to the 

current information collection 

instrument. CDC requests OMB 

approval for an estimated 120 

annualized burden hours. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Health department healthcare-associated infections/antimicrobial resistance (HAI/AR) 

program staff/epidemiologists.

B. multivorans outbreak investigation case 

report form.

40 1 3 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–20245 Filed 9–6–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Meeting of the Mine Safety and Health 

Research Advisory Committee 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting of the Mine Safety 

and Health Research Advisory 

Committee (MSHRAC). This is a hybrid 

meeting, accessible both in person and 

virtually. It is open to the public and 

limited only by the space available and 

the number of web conference lines 

available. Time will be available for 

public comment. 

DATES: The meeting will be held on 

November 7, 2024, from 8:30 a.m. to 

4:10 p.m., EST. 

ADDRESSES: University of Kentucky, 

Mining and Minerals Resources 

Building, Room 102, 310 Columbia 

Avenue, Lexington, Kentucky 40508. 

The conference room accommodates 

approximately 100 people. 

If you wish to attend the meeting 

either in person or virtually, please 

contact Ms. Berni Metzger by email at 

Metzger@cdc.gov or by phone at (412) 

386–4541 at least 5 business days in 

advance of the meeting. If you are 

attending virtually, she will provide you 

with the Zoom web conference access 

information (500 web conference lines 

are available). 

FOR FURTHER INFORMATION CONTACT: 

Steven Mischler, Ph.D., Designated 

Federal Officer, Mine Safety and Health 

Research Advisory Committee, National 

Institute for Occupational Safety and 

Health, Centers for Disease Control and 

Prevention, 626 Cochrans Mill Road, 

Pittsburgh, Pennsylvania 15236. 

Telephone: (412) 386–5688; Email: 

SMischler@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Mine Safety and Health 

Research Advisory Committee 

(MSHRAC) is charged with providing 

advice to the Secretary, Department of 

Health and Human Services; the 

Director, Centers for Disease Control 

and Prevention; and the Director, 

National Institute for Occupational 

Safety and Health (NIOSH), on priorities 

in mine safety and health research, 

including grants and contracts for such 

research, 30 U.S.C. 812(b)(2). 

Matters to be Considered: The agenda 

will include discussions on NIOSH 

mining safety and health research 

organizational structure, capabilities, 

projects, and outcomes; discussions on 

intramural and extramural silica 

research; and a verbal report from 

MSHRAC’s Mace Underground Mine 

Safety and Health Research Laboratory 

Development Workgroup. The meeting 

will also include an update from the 

NIOSH Associate Deputy Director, Mine 

Safety and Research. Agenda items are 

subject to change as priorities dictate. 

Public Participation 

Written Public Comment: The public 

may submit written comments or 

questions in advance of the meeting, to 

the Designated Federal Officer (see FOR

FURTHER INFORMATION CONTACT above). 

Written comments received in advance 

of the meeting will be included in the 

official record of the meeting, and 

questions will be answered during the 

oral comment period open to public 

participation. 

Oral Public Comment: The meeting 

will include time for members of the 

public to make an oral comment. The 

public comment session will be held on 

November 7, 2024, at 3:30 p.m., EST, or 

the conclusion of the planned 

presentations, whichever comes first. 

Members of the public will be allocated 

5 to 10 minutes each for presentations 

or comments, as a function of the 

number of commenters. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–20253 Filed 9–6–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Meeting of the Clinical Laboratory 

Improvement Advisory Committee 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 174 / Monday, September 9, 2024 / Notices 73095 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting for the Clinical 

Laboratory Improvement Advisory 

Committee (CLIAC). This is a virtual 

meeting. It is open to the public, limited 

only by the number of webcast lines 

available. Time will be available for 

public comment, and the public is also 

welcome to submit written comments in 

advance of the meeting (see the public 

participation section below). 

DATES: The meeting will be held on 

November 6, 2024, from 11 a.m. to 5 

p.m., EST, and November 7, 2024, from 

11 a.m. to 5 p.m., EST. 

ADDRESSES: This is a virtual meeting. 

Meeting times are tentative and subject 

to change. The confirmed meeting 

times, agenda items, and meeting 

materials, including instructions for 

accessing the live meeting broadcast, 

will be available on the CLIAC website 

at https://www.cdc.gov/cliac. Check the 

website for the web conference link. 

FOR FURTHER INFORMATION CONTACT: 

Heather Stang, M.S., Senior Advisor for 

Clinical Laboratories, Division of 

Laboratory Systems, Center for 

Laboratory Systems and Response, 

Office of Laboratory Science and Safety, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, 

Mailstop V24–3, Atlanta, Georgia 

30329–4027. Telephone: (404) 498– 

2769; Email: HStang@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Clinical Laboratory 

Improvement Advisory Committee 

(CLIAC) is charged with providing 

scientific and technical advice and 

guidance to the Secretary, Department 

of Health and Human Services; the 

Assistant Secretary for Health; the 

Director, Centers for Disease Control 

and Prevention (CDC); the 

Commissioner, Food and Drug 

Administration (FDA); and the 

Administrator, Centers for Medicare & 

Medicaid Services (CMS). The advice 

and guidance pertain to general issues 

related to improvement in clinical 

laboratory quality and laboratory 

medicine and specific questions related 

to possible revision of the Clinical 

Laboratory Improvement Amendments 

of 1988 (CLIA) standards. Examples 

include providing guidance on studies 

designed to improve quality, safety, 

effectiveness, efficiency, timeliness, 

equity, and patient-centeredness of 

laboratory services; revisions to the 

standards under which clinical 

laboratories are regulated; the impact of 

proposed revisions to the standards on 

medical and laboratory practice; the 

modification of the standards and 

provision of non-regulatory guidelines 

to accommodate technological 

advances, such as new test methods, 

electronic transmission of laboratory 

information, and mechanisms to 

improve the integration of public health 

and clinical laboratory practices. 

Matters to be Considered: The agenda 

will include CDC, CMS, and FDA 

agency updates. Presentations and 

CLIAC discussions will focus on reports 

from two CLIAC workgroups, the 

Biosafety Workgroup and the Next 

Generation Sequencing Workgroup; 

cybersecurity requirements in the 

clinical laboratory; the determination of 

clinically relevant range of values for 

proficiency testing samples; and the 

utilization of remote technology for 

competency assessments. Agenda items 

are subject to change as priorities 

dictate. 

Public Participation 

It is the policy of CLIAC to accept 

written public comments and provide a 

brief period for oral public comments 

pertinent to agenda items. 

Oral Public Comment: Public 

comment periods for each agenda item 

are scheduled immediately prior to the 

Committee discussion period for that 

item. In general, each individual or 

group requesting to present an oral 

comment will be limited to a total time 

of five minutes (unless otherwise 

indicated). Speakers should email 

CLIAC@cdc.gov or notify the contact 

person above (see FOR FURTHER

INFORMATION CONTACT) at least five 

business days prior to the meeting date. 

Written Public Comment: CLIAC 

accepts written comments until the date 

of the meeting (unless otherwise stated). 

However, it is requested that comments 

be submitted at least five business days 

prior to the meeting date so that the 

comments may be made available to the 

Committee for their consideration and 

public distribution. Written comments 

should be submitted by email to 

CLIAC@cdc.gov or to the contact person 

above. All written comments will be 

included in the meeting minutes posted 

on the CLIAC website. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–20252 Filed 9–6–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Solicitation of Nominations for 

Appointment to the Board of Scientific 

Counselors Infectious Diseases 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), within the 

Department of Health and Human 

Services (HHS), is seeking nominations 

for membership on the Board of 

Scientific Counselors Infectious 

Diseases (BSC ID). The BSC ID consists 

of up to 17 experts from authorities 

knowledgeable in the fields relevant to 

the issues addressed by CDC’s infectious 

disease national centers (e.g., respiratory 

diseases, healthcare-associated 

infections, antimicrobial resistance, 

foodborne diseases, zoonotic and vectorborne diseases, sexually transmitted 

diseases, preparedness) and related 

specialties, including clinical and 

public health practice (including state 

and local health departments), 

laboratory practice, research, 

diagnostics, microbiology, immunology, 

molecular biology, bioinformatics, 

infectious disease modeling and 

outbreak analytics, health policy/ 

communications, and industry. 

DATES: Nominations for membership on 

the BSC ID must be received no later 

than October 9, 2024. Packages received 

after this time will not be considered for 

the current membership cycle. 

ADDRESSES: All nominations should be 

mailed to the Centers for Disease 

Control and Prevention, BSC ID, 1600 

Clifton Road NE, Mailstop H16–5, 

Atlanta, Georgia 30329–4027 or emailed 

to SWiley@cdc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Sarah Wiley, M.P.H., Senior Advisor, 

National Center for Emerging and 

Zoonotic Infectious Diseases, Centers for 

Disease Control and Prevention, 1600 


ddrumheller on DSK120RN23PROD with NOTICES1